Expression of long noncoding RNA and clinical outcomes of pancreatic cancer patients who received adjuvant chemotherapy by S-1 or GEM after curative resection

Abstract Objective: The aim of this study was to determine the relationship between the values of several systemic inflammatory markers and the prognosis in pancreatic cancer patients treated by curative resection followed by adjuvant chemotherapy. Methods: A total of 110 pancreatic cancer patients who treated by curative resection followed by adjuvant chemotherapy were reviewed for this study. Univariate and multivariate analyses were performed to identify the clinicopathological factors influencing the overall survival, including the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), Glasgow prognostic score (GPS), and the direction of change of the NLR (increase or decrease) after one cycle of adjuvant chemotherapy as compared to the value recorded prior to the start of the chemotherapy. Results: A multivariate analysis identified only the direction of change of the NLR after the first cycle of adjuvant chemotherapy as an independent risk factor for the overall survival (NLR decrease vs. NLR increase, HR=1.925; P=0.044). The NLR, PLR and GPS were not identified as significant predictors of the overall survival. Conclusions: The direction of change of the NLR after the first cycle of adjuvant chemotherapy may help in predicting the effect of chemotherapy in pancreatic cancer patients treated by curative resection followed by adjuvant chemotherapy.

Download Full-text

The impact of dihydropyrimidine dehydrogenase expression in pancreatic cancer patients who undergo curative resection with S-1 adjuvant chemotherapy

Pancreatology ◽

10.1016/j.pan.2016.06.511 ◽

2016 ◽

Vol 16 (4) ◽

pp. S142

Author(s):

Masaaki Murakawa ◽

Toru Aoyama ◽

Yohei Miyagi ◽

Yosuke Atsumi ◽

Keisuke Kazama ◽

...

Keyword(s):

Pancreatic Cancer ◽

Adjuvant Chemotherapy ◽

Cancer Patients ◽

Curative Resection ◽

Dihydropyrimidine Dehydrogenase ◽

The Impact

Download Full-text

The Lymph Node Ratio Is an Independent Prognostic Factor in Pancreatic Cancer Patients Who Receive Curative Resection Followed by Adjuvant Chemotherapy

Anticancer Research ◽

10.21873/anticanres.12801 ◽

2018 ◽

Vol 38 (8) ◽

pp. 4877-4882 ◽

Cited By ~ 10

Author(s):

TORU AOYAMA ◽

NAOTO YAMAMOTO ◽

MARIKO KAMIYA ◽

MASAAKI MURAKAWA ◽

HIROSHI TAMAGAWA ◽

...

Keyword(s):

Pancreatic Cancer ◽

Lymph Node ◽

Adjuvant Chemotherapy ◽

Prognostic Factor ◽

Cancer Patients ◽

Curative Resection ◽

Lymph Node Ratio ◽

Independent Prognostic Factor ◽

Node Ratio

Download Full-text

Pathological tumor size is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with S-1

Annals of Cancer Research and Therapy ◽

10.4993/acrt.25.5 ◽

2017 ◽

Vol 25 (1) ◽

pp. 5-11

Author(s):

Toru Aoyama ◽

Masaaki Murakawa ◽

Koichiro Yamaoku ◽

Amane Kanazawa ◽

Akio Higuchi ◽

...

Keyword(s):

Pancreatic Cancer ◽

Adjuvant Chemotherapy ◽

Prognostic Factor ◽

Cancer Patients ◽

Tumor Size ◽

Curative Resection ◽

Independent Prognostic Factor

Download Full-text

Lymphatic invasion as an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemcitabine or S-1.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.4_suppl.290 ◽

2016 ◽

Vol 34 (4_suppl) ◽

pp. 290-290

Author(s):

Keisuke Kazama ◽

Toru Aoyama ◽

Yusuke Katayama ◽

Koichiro Yamaoku ◽

Masaaki Murakawa ◽

...

Keyword(s):

Pancreatic Cancer ◽

Adjuvant Chemotherapy ◽

Prognostic Factor ◽

Cancer Patients ◽

Curative Resection ◽

Lymphatic Invasion ◽

Independent Prognostic Factor ◽

Rank Test ◽

Curative Surgery ◽

Novel Treatments

290 Background: The objective of this retrospective study was to clarify prognostic factors in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemcitabine or S-1. Methods: Both overall survival (OS) and recurrence-free survival (RFS) were examined in 122 pancreatic cancer patients who underwent curative surgery and received adjuvant gemcitabine or S-1 after surgery between 2005 and 2014. Results: When the length of OS was evaluated according to the log-rank test, significant differences were observed in lymphatic invasion and the T status. Univariate and multivariate Cox’s proportional hazard analyses demonstrated that lymphatic invasion was the only significant independent prognostic factor for both OS and RFS. The 5-year OS was 30.1% in the lymphatic invasion-negative group and 12.1% in the lymphatic invasion-positive group (p < 0.001). Moreover, the 5-year RFS was 20.5% in the lymphatic invasionnegative group and 10.4% in the lymphatic invasionpositive group (p = 0.006). Conclusions: Lymphatic invasion is the most important prognostic factor for OS and RFS in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherapy. The present results suggest that adjuvant chemotherapy is not sufficient, especially in patients with risk factors. Such patients should be evaluated as a target group for clinical trials of novel treatments.

Download Full-text